

CHAP TEAM Newsletter

WHATS NEW?



The CHAP team travelled to Port Lincoln for the first time on the 27th October for a codesign workshop with cardiac rehab consumers.

WE'VE COMPLETED Roadshow no 2!

OCTOBER

2021



GRANTS

GRANTS IN PROGRESS

- 1. Australian government PhD Scholarship (Katie Nesbitt)
- 2. Astra Zeneca for further support for the CHAP Project
- 3. Wellbeing SA: Chronic Disease Integrated Partnership Grant
- 4. Flinders University Infrastructure Grant
- 5. MRFF CVD Mission (Integrated Care and Access)

AWARDED!

Our team was awarded a Flinders DVCR Research Infrastructure grant which will allow us to purchase two new high specification computers for the upcoming analysis of the data from the linkage project

TEAM PRESENTATIONS

Our team will be presenting at the Australian Telehealth Society Conference – Successes and Failures in Telehealth from the 3rd to 5th of November

Stephanie Champion, Flinders University

The experiences of telehealth and in-person cardiac rehabilitation services during COVID-19 and the impact on patient engagement

Alline Beleigoli, Flinders University

The Country Heart Attack Prevention (CHAP) Project: a telehealth-based model of care to improve attendance to cardiac rehabilitation of Australians living in rural and remote areas

Katie Nesbitt, Flinders University

Person centred co-design methodology for web portal delivery of services to engage and improve attendance of rural and remote patients in cardiac rehabilitation

DATA LINKAGE PROJECT

THE DATA LINKAGE PROJECT HAS RECEIVED GOVERNANCE AUTHORISATION FROM DHW, CALHN AND YORKE AND NORTHERN LOCAL HEALTH NETWORK. WE ARE NOW SEEKING TO FINALISE THE GOVERNANCE PROCESS WITHIN THE OTHER REGIONAL LOCAL HEALTH NETWORKS.

WHATS ON IN NOVEMBER?



CONTINUAL PROFESSIONAL DEVELOPMENT SESSION: WITH PROFESSOR ROBYN CLARK

TOPIC: 'THE SCIENCE BEHIND THE CATCH PRE AND POST ASSESSMENT DATA COLLECTION AND SA HEALTH DATA DRIVEN PRACTICE'

WHEN: WEDNESDAY, NOVEMBER 10TH TIME: 1PM-1:45PM WHERE: ZOOM

CHAP PHARMACIST Dr Lemlem Gebremichael

Adverse effects of the new primary CVD prevention polypill could limit their clinical use



